eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
– Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 –
– Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation –
Related news for (EFTR)
- eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
- eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer